Cabot Sweeney, MD
Family Medicine · Lees Summit, MONPI 1912999277
Payments from drug & device makers
Across 171 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$402
- Pfizer$352
- Novo Nordisk$275
- Boehringer Ingelheim$236
- AstraZeneca$225
- Johnson & Johnson$177
- plus $926 from 19 others
What the payments were for
- Food & beverage$2,593100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $402 |
| Pfizer | 29 | $352 |
| Novo Nordisk | 18 | $275 |
| Boehringer Ingelheim | 15 | $236 |
| AstraZeneca | 15 | $225 |
| Johnson & Johnson | 11 | $177 |
| Lilly USA, LLC | 10 | $161 |
| Amgen | 7 | $102 |
| Astellas Pharma US Inc | 5 | $86 |
| Merck | 6 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| GSK | 3 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Bayer | 2 | $37 |
| Exact Sciences | 2 | $37 |
| Abbott | 2 | $35 |
| Shire North American Group Inc | 2 | $31 |
| Novartis | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $25 |
| Eisai Inc. | 2 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
How this compares
$2,593 in reported general payments places this provider in the 75th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $76,118 |
| EliquisApixaban | 23 | $34,438 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $31,180 |
| MounjaroTirzepatide | 18 | $25,597 |
| XareltoRivaroxaban | 20 | $23,991 |
| SynjardyEmpagliflozin/Metformin Hcl | 13 | $20,086 |
| TrulicityDulaglutide | 23 | $18,156 |
| FarxigaDapagliflozin Propanediol | 25 | $17,523 |
| LinzessLinaclotide | 18 | $15,733 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 36 | $10,264 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $7,239 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 181 | $4,060 |
| Pantoprazole Sodium | 222 | $3,935 |
| Atorvastatin Calcium | 333 | $2,739 |
| Gabapentin | 163 | $2,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $275 | $76,11857 claims |
| Lilly USA, LLCMounjaro, Trulicity | $161 | $43,75441 claims |
| GSKTrelegy Ellipta, Arexvy | $44 | $41,44469 claims |
| PfizerEliquis | $352 | $34,43823 claims |
| Johnson & JohnsonXarelto | $177 | $23,99120 claims |
| Boehringer IngelheimSynjardy | $236 | $20,08613 claims |
| AstraZenecaFarxiga | $225 | $17,52325 claims |
| AbbVieLinzess | $402 | $15,73318 claims |
| MerckJanumet Xr | $82 | $7,23911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Lees Summit
- Veronica AnwuriLees Summit$31K
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.